Effects of Lutein Supplementation on Cognition and MPOD in Multiple Sclerosis Patients-

Status unconfirmed · Not applicable · Has a placebo group

Conditions studied: Multiple Sclerosis

In brief

The central hypothesis is that lutein supplementation will improve MPOD and cognition. Accordingly, the specific aims are to 1) to determine the process feasibility associated with participating in 4-month lutein supplementation trial; and 2) to investigate the scientific feasibility of 4-month daily lutein supplementation on biological markers of lutein status and cognitive function among persons with MS.

Key facts

Study ID

NCT04843813

Run by

University of Illinois at Urbana-Champaign

People needed

60

Starts

2021-03-26

Expected to finish

2023-03-01

Last updated by the study team

2021-04-15

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18-64.9 years
• Self-reported relapsing-remitting MS (RRMS) diagnosis
• Expanded Disability Status Scale (EDSS) score between 0-3.5
• Macular Pigment Optical Density at baseline (MPOD ≤0.35)
• Score ≤55 during the Symbol Digit Modalities Test (SDMT)
• 20/20 or corrected vision
• No presence of color blindness
• No history of age-related macular degeneration
• No history of epileptic seizures

You may not qualify if…

• Under 18 years or over 64.9 years
• MS diagnosis other than RRMS
• Pregnancy
• Uncorrected vision
• Presence of color blindness
• PDDS score of 7 or more
• Prior diagnosis of age-related macular degeneration
• History of epileptic seizures

Where it is running

• University of Illinois at Urbana-Champaign — Urbana, Illinois, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.